Fish oil supplementation in relation to the risk of chronic kidney disease among patients with diabetes

Abstract

AbstractAimTo investigate the association between fish oil supplementation and subsequent risk of chronic kidney disease (CKD) among patients with diabetes, and further evaluate the mediation effect of typical glycolipid and inflammatory biomarkers.MethodsIn total, 24 497 patients with diabetes from the UK Biobank were included. Cox proportional hazards regression models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for CKD risk, and the rate advancement period was calculated to quantify and communicate the impact of fish oil upon that risk. In addition, we also used mediation analysis to assess the mediating role of plasma biomarkers.ResultsOverall, 7122 patients reported taking fish oil supplements. During a mean of 11.3 years of follow‐up, 3533 CKD cases occurred. In the fully adjusted model, fish oil use was inversely associated with the incidence of CKD (HR 0.90; 95% CI: 0.83, 0.97), which was mediated by serum levels of HbA1c (4.7%), C‐reactive protein (CRP) (3.4%) and high‐density lipoprotein cholesterol (HDL‐C) (2.3%). Participants who took fish oil supplements displayed the same risk of CKD events, but that risk was delayed by approximately 2.79 years compared with non‐users of fish oil.ConclusionsOur findings advocate the beneficial role of fish oil use in preventing CKD among patients with diabetes, which may be mediated by serum levels of HbA1c, CRP and HDL‐C, and support public health policies aiming to promote fish oil supplementation for the prevention of diabetes complications.